The systematic review by Savaris and colleagues 1 in this issue of Sexually Transmitted Infections is important for two reasons. First, the review of the treatment of pelvic inflammatory disease (PID), a common condition for which the management is contentious, driven by traditions and not necessarily evidence-based. Second, the publication of this abridged review will help to strengthen links between the Sexually Transmitted Infections Cochrane Review (STICRG, https://sti.cochrane.org/) 3 Metronidazole is widely recommended to treat vaginal anaerobic bacteria that are often found in women with PID, but whose role in upper genital tract infection is still not proven. 4 Regimens that do not contain metronidazole could reduce adherence to antibiotic regimens and reduce concern about suggestions. If appropriate, the authors should take these changes into account when they update their Cochrane Review. 7) If changes to the manuscript result in differences in the results or the conclusions of the systematic review, the authors must discuss the changes with the STICRG.
